Elizabeth is a Senior Policy Analyst (Law and Regulation) in the humanities team. She works on legal and ethical issues for data protection, medical devices, artificial intelligence, and other technologies at the cutting-edge of health innovation.
Recent projects include:
- the value of in silico (computer simulation) trials as a new approach methodology for health
- when synthetic data might amount to personal data
- data protection and mental capacity challenges for newborn genome sequencing and for generating lifetime genomic health records
- the ethical and legal issues of using AI for pathology screening in Oesophageal Cancer Pathways
- the ethical and legal challenges of using a risk algorithm for stratifying risk in symptomatic patients in oesophageal cancer pathways
- the value of data trust and data intermediaries for health
- the challenges facing the European Health Data Space
- updates to Medical Device Regulation in the UK, EU and US, particularly on regulating adaptive devices
- the ethical and legal issues of diversifying genomic data
Elizabeth holds a PhD (medical law and ethics) from the University of Southampton where she analysed whether the definition of brain death is discriminatory towards patients with severe cognitive disability (i.e., vegetative state, minimally conscious state and comatose patients). Her research focused on consciousness, personhood and best interests’ decision-making in the Court of Protection and holds broader interests such as property law’s relationship with the human body and AI consciousness. She has presented aspects of her research at the International Conference on Clinical Ethics and Consultation at Oxford University and at the Law and Society Association Conference in Toronto, Canada.
Elizabeth has taught criminal law at the University of Southampton and medical law and ethics at Imperial College London. She was a Committee Member of the Institute of Medical Ethics’ Postgraduate Bioethics Committee (PGBC) and a postgraduate researcher at Southampton University’s Health, Ethics and Law research group (HEAL).
- Journeys, experiences and best practices on computer modelled and simulated regulatory evidence (with InSilicoUK, MHRA, the Royal Academy of Engineering)
- Adopting a risk tool for stratification and predictive prevention of oesophageal cancer
- Human involvement in AI-driven digital pathology pathways: ethical and legal considerations
- Are synthetic health data ‘personal data’?
- The European Health Data Space Regulation has arrived
- When are synthetic health data personal data? (published by GA4GH)
- Innovative regulation: keeping pace with genomics and software devices
- Are data trusts trustworthy?
- High-fiedlity synthetic patient data applications and privacy considerations. Myles, P., Mitchell, C., Redrup Hill, E., Foschini, L., Wang, Z.. Journal of Data Protection & Privacy, Vol. 6, 4 (2024) https://doi.org/10.69554/LQOM5698
- Ethical and legal implications of implementing risk algorithms for early detection and screening for oesophageal cancer, now and in the future. Tanya Brigden, Colin Mitchell, Elizabeth Redrup Hill and Alison Hall. PLOS ONE. 2023 October. https://doi.org/10.1371/journal.pone.0293576
- Ethical and legal considerations influencing human involvement in the implementation of artificial intelligence in a clinical pathway: A multi-stakeholder perspective. Elizabeth Redrup Hill, Colin Mitchell, Tanya Brigden and Alison Hall. Frontiers in Digital Health. 2023 March. https://doi.org/10.3389/fdgth.2023.1139210